Newsroom

Download PDF BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September, including: 2022 Wells Fargo Healthcare Conference Date:

Download PDF – Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100.0 million to $110.0 million – – Company Streamlines Planned R&D Spending and Lowers Guidance to $50.0 million from $60.0 million to $70.0 million – – Company to host conference call

Download PDF BOSTON, July 28, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 4, 2022, to discuss the financial results and provide

Download PDF – This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada – – AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clinical Trial in HPV Negative R/M HNSCC Expected in 1H 2023 – BOSTON, June 22, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq:

Download PDF BOSTON, June 21, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines

Download PDF Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib Latest analysis of Phase 2 study show tivozanib demonstrated promising activity in nccRCC patients, a difficult to treat patient population

Download PDF BOSTON, May 18, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. eastern time. A live webcast of the fireside chat can be accessed by

Download PDF – Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million ofFOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – – Company to Host Conference Call Today at 8:30 a.m. ET – BOSTON, May 05, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a